Cecilia Chika Unegbu

Cecilia Chika Unegbu

Auto-generated profile, based on publicly available information

Cecilia Chika Unegbu

Department of Natural Sciences, Bowie State University, Jericho Park Rd, Bowie, MD, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Journal of Cancer and Tumor International
Verified
Journal Article
Closed access
FEFortune Itoje Ebiala
Fortune Itoje Ebiala
CUCecilia Chika Unegbu
Cecilia Chika Unegbu
POPrecious Oluwamosope Okunola
Precious Oluwamosope Okunola
OCOgochi Blessing Chukwuneke
Ogochi Blessing Chukwuneke
OOOlolade Funke Olaitan
Ololade Funke Olaitan
DODamilola Ayodele Ojo
Damilola Ayodele Ojo
Beyond the human genetic codes, epigenetics also plays a key role in regulating how genes are expressed. While mutations or genes are known to be major causes of cancer, Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNAs, play critical roles in cancer progression by altering gene expression without involving DNA sequences, yet their complexity challenges traditional analytical approaches. This review aims to elucidate how digital technologies such as artificial intelligence (AI) and machine learning (ML) uncover novel epigenetic patterns beyond DNA mutations, enhancing cancer diagnosis, prognosis, and treatment. A comprehensive literature review was conducted, analysing peer-reviewed studies from rom recent reports on PubMed, Scopus, and bioinformatics databases, focusing on AI applications in several cancers such as breast, lung, and colorectal. Findings reveal that ML algorithms, including random forests, convolutional neural networks, and autoencoders, identify epigenetic signatures some of which are methylation patterns and histone modifications with up to 60–90% of cases with high accuracy. These signatures enable early detection, as demonstrated in a pancreatic cancer study achieving 87% sensitivity using ctDNA methylation. AI-driven multi-omics integration has so far uncovered synergistic interactions, improving metastasis prediction by 15–20% in ovarian cancer. Additionally, AI facilitates personalized epigenetic therapies, with models predicting response to histone deacetylase inhibitors in multiple myeloma with 90% accuracy. However, there are limitations to overcome. Some of which are data heterogeneity and model interpretability which exists in the nuances of machine systems. Ongoing research are currently exploring federated learning and explainable AI to address imminent challenges which would enhance generalizability and clinical trust. Future directions include single-cell epigenomics and AI applications in rare cancers to democratize precision medicine. Collaborative efforts among data scientists, clinicians, and biologists are essential to translate these insights into transformative cancer care.

19 September 2025 in Australian Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
SASalvation Ifechukwude Atalor
Salvation Ifechukwude Atalor
ASAliaa Mohammed Mahmoud Soliman
Aliaa Mohammed Mahmoud Soliman
OAOluwatobiloba Kehinde Adedokun
Oluwatobiloba Kehinde Adedokun
AAAbayomi Modinat Aina
Abayomi Modinat Aina
CUCecilia Chika Unegbu
Cecilia Chika Unegbu
AOALIYU OLANREWAJU OLANIYI
ALIYU OLANREWAJU OLANIYI
Background: Small-molecule drugs have transformed oncology, but conventional inhibitors are limited by resistance, restricted target scope, and declining durability. Methods: We reviewed emerging small-molecule modalities—molecular glues, covalent inhibitors, and radiotheranostics—focusing on their mechanisms, clinical applications, and translational challenges. Key clinical trials and representative examples were identified from recent oncology literature. Results: Molecular glues enable targeted degradation of previously undruggable proteins, with clinical success in multiple myeloma (IMiDs). Covalent inhibitors achieve durable suppression of oncogenic drivers such as KRAS^G12C and BTK, as shown in CodeBreaK100 (sotorasib; N=126; ORR 37%). Radiotheranostics combine imaging and therapy, exemplified by VISION (PSMA-617; N=831; OS HR 0.62) and NETTER-1 (Lutathera; N=229; PFS HR 0.21). Collectively, these modalities expand the druggable proteome, improve durability, and advance precision oncology. Conclusion: Emerging small-molecule approaches mark a paradigm shift from inhibition alone to targeted degradation, durable covalent engagement, and diagnostic–therapeutic hybrids. Future priorities include improving selectivity, biomarker integration, scalable manufacturing, and equitable global access.